References
Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568–75.
Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929–37.
Ku EC, Raychaudhuri A, Ghai G, Kimble EF, Lee WH, Colombo C, et al. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta 1988;959:332–42.
Sweeny FJ, Eskra JD, Carty TJ. Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood. Prost Leukotrienes Med 1987;28:73–93.
Kimble E, Kowalski T, White D, Raychaudhuri A, Pastor G, Chertock H, et al. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase. Agents Actions 1991;34:125–8.
Almeida AP, Bayer BM, Horakova Z, Beaven MA. Influence of indomethacin and other anti-inflammatory drugs on mobilization and production of neutrophils: studies with carrageenaninduced inflammation in rats. J Pharmacol Exp Ther 1980;214:74–9.
Tsunoda H, Abe S, Sakuma Y, Katayama S, Katayama K. Involvement of leukotriene C4 in PAF-induced death in mice. Prost. Leukotrienes and Essential Fatty Acids 1990;39:291–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kimble, E., Kowalski, T., Peters, P. et al. CGS 26529: The biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action. Inflamm Res 44 (Suppl 2), S147–S148 (1995). https://doi.org/10.1007/BF01778305
Issue Date:
DOI: https://doi.org/10.1007/BF01778305